We advised the sole bookrunner and representative of the several underwriters on the offering

Davis Polk advised the sole bookrunner and representative of the several underwriters in connection with a public offering by Immix Biopharma, Inc. of 19,117,646 shares of common stock at $5.10 per share and pre-funded warrants to purchase 490,196 shares of common stock at $5.09 per pre-funded warrant for total gross proceeds of approximately $100 million. The common stock is listed on the Nasdaq Capital Market under the symbol “IMMX.”

Immix Biopharma is a clinical-stage biopharmaceutical company focused on the application of chimeric antigen receptor therapy (CAR-T) in light chain (AL) amyloidosis and other serious diseases.

The Davis Polk corporate team included partners Alan F. Denenberg and Beth LeBow and associates Julia Molo and Matthew Franklin. Counsel Christopher A. Baratta and associate Nancy B. Regan provided tax advice. Partner David R. Bauer and associate Gabrielle Mazero provided intellectual property advice. Members of the Davis Polk team are based in the Northern California and New York offices.

Copy link to share post